Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Therapy

Liraglutide — preventing or postponing T2DM diagnosis?

Nature Reviews Endocrinology volume 13, pages 320–322 (2017)Cite this article

Subjects

Treatment with liraglutide (3.0 mg once daily for 3 years), a glucagon-like peptide 1 receptor agonist that lowers levels of glucose and reduces body weight, reduced the risk of 'on treatment' type 2 diabetes mellitus (T2DM) versus placebo in patients with prediabetes and obesity. Whether this treatment affects the natural history of the progression from prediabetes to T2DM remains to be established.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Masters, R. K. et al. The impact of obesity on US mortality levels: the importance of age and cohort factors in population estimates. Am. J. Public Health 103, 1895–1901 (2013).

    Article  Google Scholar 

  2. The American Society for Metabolic and Bariatric Surgery, The Obesity Society, The American Society of Bariatric Physicians and American Association of Clinical Endocrinologists. Obesity is a disease: leading obesity groups agree. PR Newswire http://www.prnewswire.com/news-releases/obesity-is-a-disease-leading-obesity-groups-agree-212194851.html (2013).

  3. Knowler, W. C. et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 346, 393–403 (2002).

    Article  CAS  Google Scholar 

  4. Tabák, A. G., Herder, C., Rathmann, W., Brunner, E. J. & Kivimäki, M. Prediabetes: a high-risk state for diabetes development. Lancet 379, 2279–2290 (2012).

    Article  Google Scholar 

  5. Khera, R. et al. Association of pharmacological treatments for obesity with weight loss and adverse events: a systematic review and meta-analysis. JAMA 315, 2424–2434 (2016).

    Article  CAS  Google Scholar 

  6. Lund, A., Knop, F. K. & Vilsbøll, T. Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: differences and similarities. Eur. J. Intern. Med. 25, 407–414 (2014).

    Article  CAS  Google Scholar 

  7. Blonde, L. & Russell-Jones, D. The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1–5 studies. Diabetes Obes. Metab. 11 (Suppl. 3), 26–34 (2009).

    Article  CAS  Google Scholar 

  8. Wadden, T. A. et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. Int. J. Obes. (Lond.) 37, 1443–1451 (2013).

    Article  CAS  Google Scholar 

  9. le Roux, C. W. et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet 389, 1399–1409 (2017).

    Article  CAS  Google Scholar 

  10. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 33 (Suppl. 1), S62–S69 (2010).

Download references

Author information

Authors and Affiliations

  1. Denmark; and at the Department of Clinical Medicine, Steno Diabetes Center Copenhagen, University of Copenhagen, Niels Steensens Vej 2, DK-2820 Gentofte, Denmark; University of Copenhagen, The Panum Institute, Blegdamsvej 3, DK-2100 Copenhagen, Denmark.,

    Tina Vilsbøll

  2. Center for Diabetes Research, Gentofte Hospital, University of Copenhagen, Kildegårdsvej 28, DK-2900 Hellerup, Denmark,

    Tina Vilsbøll

  3. Denmark; and at the Department of Clinical Medicine, Center for Diabetes Research, Gentofte Hospital, University of Copenhagen, Kildegårdsvej 28, DK-2900 Hellerup, University of Copenhagen, The Panum Institute, Blegdamsvej 3, DK-2100 Copenhagen, Denmark.,

    Filip K. Knop

  4. and at the Department of Clinical Medicine, University of Copenhagen, The Panum Institute, Blegdamsvej 3, DK-2100 Copenhagen, Denmark.,

    Filip K. Knop

Authors
  1. Tina Vilsbøll
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Filip K. Knop
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tina Vilsbøll.

Ethics declarations

Competing interests

Within the past 36 months, T.V. has served on scientific advisory panels and/or speaker's bureaus for, served as a consultant to and/or received research support from Amgen, AstraZeneca, Boehringer, Bristol-Myers Squibb, Eli Lilly, Merck Sharp & Dohme, Novo Nordisk and Sanofi. Within the past 36 months, F.K.K. has served on scientific advisory panels and/or speaker's bureaus for, served as a consultant to and/or received research support from Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Fractyl, Gubra, Merck Sharp & Dohme, Novo Nordisk, Sanofi and Zealand Pharma.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Vilsbøll, T., Knop, F. Liraglutide — preventing or postponing T2DM diagnosis?. Nat Rev Endocrinol 13, 320–322 (2017). https://doi.org/10.1038/nrendo.2017.55

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrendo.2017.55

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing